Concepedia

Author

J P Guastalla

Institut Jean Godinot

Also Known As

D Paraiso, Guastalla, J. P., J P Guastalla, J-P Guastalla, J. Guastalla, J.-P. Guastalla, J.P Guastalla, J.P. Guastalla, JP Guastalla, P Clavère

24

Publications

556

Citations

11

H-Index

25

Concepts

All Affiliations

Institut Jean GodinotInstitut BergoniéInstitut National du CancerInstitute Cancer De La Loire Lucien NeuwirthCentre de Recherche en Cancérologie de Lyon
JP

About

J P Guastalla is an author at Institut Jean Godinot specializing in medicine, cancer therapeutics, and breast cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

420

2

Health Sciences

3

3

114

3

Obstetrics

2

2

181

4

Pharmacology

2

2

98

5

Orthopaedics

1

1

122

J P Guastalla

×

9

Publications

498

Citations

9

H-Index

YearCitations

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled,

The Lancet

2019

125

Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates

Cyrille B. Confavreux, A Fontana, J P Guastalla,

Bone

2007

122

Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).

T Bachelot, C. Bourgier, Claire Cropet,

Cancer Research

2010

61

A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.

M.-A. Mahé, P. Fumoleau, Michel Fabbro,

PubMed

1999

59

Clinical Phase I and Pharmacology Study of Gemcitabine (2', 2'-Difluorodeoxycytidine) Administered in a Two-Weekly Schedule

Godefridus J. Peters, M. Clavel, Paul Noordhuis,

Journal of Chemotherapy

2007

42

Abstract S5-3: PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer

Xavier Pivot, Gilles Romieu, Hervé Bonnefoi,

Cancer Research

2012

37

Phase I study of gemcitabine using a once every 2 weeks schedule

J. B. Vermorken, J P Guastalla, SR Hatty,

British Journal of Cancer

1997

25

Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer

Xavier Pivot, Gilles Romieu, Hervé Bonnefoi,

Annals of Oncology

2012

16

Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.

Éric Pujade-Lauraine, J P Guastalla, B. Weber,

PubMed

1997

11

Page 1